We describe a novel assay for measuring glycohemoglobin directly from anticoagulated whole blood with the Abbott lMx#{174} analyzer. The glycohemoglobinis labeled with a soluble polyanionic affinity reagent and the anionic complex is then captured with a cationic solid-phase matrix. Glycohemoglobin is quantified by measuring the quenching by heme of the static fluorescence from an added fluorophore. The assay is standardized to report both percent total glycohemoglobin (%GHb) and percent hemoglobin A1 (%HbA1). Glucose, bilirubin, triglycerides, labile fraction, and hemoglobin variants do not interfere in the assay. Within-and between-run CVs are -4-5%, with total CVs of -6.5%. Highly significantlinear correlations (r >0.97) were obtained in comparison studies with two major assay methodologies. The time to obtain one result is -10 mm (including assay of a control), 56 mm for 22 results. We describe the development, standardization, and validation of this new method. 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide.
niques have been discussed (2). In general, the first two methods are subject to interference from numerous preand posttranslational phenomena unrelated to glycation that alter the hemoglobin charge relative to unmodified hemoglobin A0. This includes hemoglobin variants, such as sickle and fetal hemoglobin, and labile Schiff base intermediates (3). Boronate affinity chromatography has the advantage of being insensitive to almost all of the interferences and limitations of ion-exchange chromatography. However, commercial boronate chromatography methods are generally labor-intensive and uncalibrated, which can result in variation of measurements between laboratories, lots, and manufacturers
(4).
Despite the limitations of cation-exchange methods, ion-exchange HPLC has gained significant acceptance as a "reference" method for glycohemoglobin. We have developed a fully automated batch assay of glycohemoglobin, based on novel principles for separation and detection. The method utilizes boronate affinity chemistry and is therefore insensitive to hemoglobin variants, labile fraction, and other interferences that affect cation-exchange methods. The assay is performed with a nondedicated bench-top analyzer and is standardized to report %GHb as well as %HbA1, in accordance with the method used in the DCCT (9) . In this report, we describe the development, standardization, and validation of the new method. We also show comparison data between this method and ion-exchange HPLC chromatography, boronate affinity chromatography, and the glycohemoglobin assay recently developed for the Abbott Visiones instrument (10).
Standard-

MaterIals and Methods
Apparatus
The 
Assay Principle and Protocol
The IMx Glycated Hemoglobin assay utilizes a recently developed separation technology based on polyelectrolyte interaction (12). In this approach, the glass fiber matrix of the IMx disposable reaction cell is precoated with a high-molecular-mass quaternary ammomum compound. This imparts a net positive charge to the matrix, which enables electrostatic capture of anionic analyte-carrier complexes. In the IMx Glycated Hemoglobin assay, anionic complexes are formed between molecules of glycohemoglobin and a polyaniomc affinity reagent composed of polyacrylic acid and dihydroxyboronate.
The specificity of the assay is based on the interaction between the dihydroxyboronate component of the affinity reagent and the cis-diols of the glycohemoglobin (13). Glycohemoglobin is separated from nonglycohemoglobin through the electrostatic interaction between the polyacrylic acid component of the affinity reagent and the cationic solid phase (see Figure  1) The total MU present in the system is the unbound plus the bound:
Similnrly, the total MU fluorescence is: 
Standardization
The boronate component of the polyanionic affinity reagent is specific for all glycohemoglobins calibration to a primary reference HPLC system (9). These specimens were then tested in replicates of two in each of three IMx instruments across three separate reagent lots (2 replicates x 3 instruments =6 replicates per specimen; one reagent lot per specimen; reagent lots changed after every 80 specimens). The IMx instruments were in run mode 0 (calibration) for the first replicate and in mode 1 (curve storage) for the second replicate, with the replicates being assayed on separate days. In all, 24 separate calibration curves were used in the study.
(13). Thus the
Model Studies
The standardization data were carefully analyzed to These data, and our second-order fit (from a zero origin), are shown in the inset of Figure 5 of the present report. The second-order fit closely approximated the curved data (r2 = 1.000). 
Specimens
Unless otherwise noted, whole-blood specimens were collected in EDTA anticoagulant and stored at 2-8 #{176}C. Specimens were assayed by all methods 1 week after collection.
Specimens that were tested out-of-house (HPLC method comparisons) were assayed soon after collection and then were shipped in insulated containers with ice packs to Abbott via overnight delivery.
Statistical Methods
Statistical analysis was done with the FASTAT software package (Systat Inc., Evanston, IL). Parametric tests included simple linear regression, t-tests, and analysis of variance
(ANOVA). Probability plots were used to examine residual error distribution.
Leverage values and Student's t-test residuals were used to analyze error variance and integrity
of the regression coefficient estimates. The standard curve-fit method was a four-parameter logistical fit. Labile fraction. Four anticoagulated whole-blood specimens with different hemoglobin concentrations were incubated for 3 h with glucose, 14 g/L, to generate labile fraction (23). Immediate testing after the 3 h showed no effect from labile fraction on the IMx results (data not shown).
Results and DIscussion
Calibration Curves
Hemoglobin
variants. Three common hemoglobin variants (HbAC, HbAS, HbF) were identified by ionexchange chromatography (Bio-Rad Diamat) and tested in the IMx. An affinity chromatography method (Isolab Glyc-Affin, lot 109008) was used for reference because of
Assay Precision
Precision was evaluated by assaying four replicates of each of three IMx Glycated Hemoglobin controls twice a day on nine different days over a 21-day period with 10 IMx instruments, giving a total of 720 determinations at each control concentration.
Precision was determined according to Krouwer and Rabinowitz (24). Concentrations were calculated from stored calibration curves run on the first day of the study. Stored curves were adjusted during each run by using the B calibrator.
Pooled coefficients of variance across all 10 instruments were 4.3%, 4.4%, and 4.4% (between-run);
5.3%, 4.8%, and 4.5% (within-run); and 6.8%, 6.5%, and 6.3% (total) for controls containing 5.5%, 10.9%, and 19.6% GHb, respectively. These numbers estimate the expected long-term assay variability on a given IMx instrument.
Reference Interval
The average value for %GHb from 101 presumably nondiabetic men and women (Abbott employees) was 5.67% (SD 0.38%); 97% of the values were <6.43% GlIb. Based on these data, our estimate of the 2SD reference interval for %GHb is therefore 4.9-6.4%, and 4.5-5.5% for standardized %HbA1.
For comparison, %GHb results obtained with Isolab Glyc-Aflln (lot 109008) were: mean 5.55%, SD 0.52%, 2SD normal range 4.5-6.6%.
Standardization
Correlation with the reference HPLC assay. The correlation between IMx (%GHb) and the secondary reference
is shown in Figure 3 . IMx reagent lots were changed three times at equal intervals over the course of the study. No significant differences were noted between reagent lots or IMx instruments a 25% decrease in correlation slope (not shown). A control study with split samples indicated that the discrepancy was due to a difference between the two Glyc-AflIn lots. A statistically significant difference between affinity chromatography lots has been reported previously (27).
In conclusion, the fully automated assay described in this report should represent a significant advance in batch testing for glycohemoglobin.
In addition, standardization to an ion-exchange reference method permits comparison of results with those of other methodologies standardized to the same reference assay.
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